CASTLE BIOSCIENCES INC
Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.
Castle Biosciences (CSTL) announced a study published in the Journal of the American Academy of Dermatology validating its DecisionDx-SCC test for high-risk cutaneous squamous cell carcinoma. The test integrates molecular data with clinicopathologic risk factors, demonstrating a 97.3% negative predictive value for low-risk patients and identifying those likely to benefit from adjuvant radiation therapy. The study involved 572 patients and showed the test's ability to stratify metastatic and loca
SciBase (private) received an additional order from Castle Biosciences (CSTL) for their ongoing collaboration on atopic dermatitis studies. Deliveries are expected to start in Q4 2026. The order accelerates the initial study and prepares for a second one. SciBase's CEO, Pia Renaudin, expressed excitement about the collaboration's progress.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CSTL (CASTLE BIOSCIENCES INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CSTL coverage spans insider activity, technology and financial news.
In the last 30 days, CSTL insiders filed 14 SEC Form 4 transactions — no purchases and 14 sales ($1.4M). The most active reporter was MAETZOLD DEREK J, Pres. & Chief Exec. Officer, with 9 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive clinical data may boost adoption of TissueCypher, supporting revenue growth.
The study may enhance market perception of Castle's diagnostic platform and support future adoption, but immediate price impact is limited.
SciBase (private) received an additional order from Castle Biosciences (CSTL) for their ongoing collaboration on atopic dermatitis studies. Deliveries are expected to start in Q4 2026. The order accelerates the initial study and prepares for a second one. SciBase's CEO, Pia Renaudin, expressed excitement about the collaboration's progress.
The insider sale may signal reduced confidence and could pressure the stock short-term.
An insider open-market sale on a non-10b5-1 plan can add short-term sentiment noise, but it is not a fundamental catalyst by itself.
AlphAI scores every news story that mentions CSTL with an AI model for sentiment and relevance, and aggregates insider trades from CASTLE BIOSCIENCES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.
2 min readCastle Biosciences (CSTL) announced a study published in the Journal of the American Academy of Dermatology validating its DecisionDx-SCC test for high-risk cutaneous squamous cell carcinoma. The test integrates molecular data with clinicopathologic risk factors, demonstrating a 97.3% negative predictive value for low-risk patients and identifying those likely to benefit from adjuvant radiation therapy. The study involved 572 patients and showed the test's ability to stratify metastatic and loca
2 min readSciBase (private) received an additional order from Castle Biosciences (CSTL) for their ongoing collaboration on atopic dermatitis studies. Deliveries are expected to start in Q4 2026. The order accelerates the initial study and prepares for a second one. SciBase's CEO, Pia Renaudin, expressed excitement about the collaboration's progress.
1 min readOelschlager Kristen M (Chief Operating Officer) sold 24,602 indirectly-held shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $34.06 ($33.69–$34.64, $0.84M total) across 3 trades over 2026-08-24 to 2026-08-25.
1 min readStokes Frank (Chief Financial Officer) sold 24,908 shares of CASTLE BIOSCIENCES INC (CSTL) at $29.77 ($0.74M total) on 2026-08-14.
2 min readCastle Biosciences (CSTL) said Nasdaq approved a dual listing on Nasdaq Texas while keeping its primary Nasdaq Global Market listing under ticker CSTL. The company reported Q2 2026 revenue of $103.5 million vs $86.2 million a year earlier, gross margin 75%, net loss $2.1 million, and raised FY2026 revenue guidance to $365 million-$375 million. Cash was $266.8 million as of June 30, 2026.
4 min readCastle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.
6 min readMAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 16,114 indirectly-held shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $31.08 ($30.68–$31.34, $0.50M total) across 6 trades over 2026-08-04 to 2026-08-05 under a Rule 10b5-1 trading plan.
2 min readMAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 22,902 shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $31.06 ($30.68–$31.34, $0.71M total) across 3 trades over 2026-08-04 to 2026-08-05 under a Rule 10b5-1 trading plan.
2 min readJuvenal Tobin W (Chief Commercial Officer) sold 19,040 shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $29.21 ($28.25–$30.26, $0.56M total) across 4 trades over 2026-07-31 to 2026-08-03 under a Rule 10b5-1 trading plan.
1 min read
